IMvigor 210: Phase 2 trial of atezolizumab, anti-PD-L1, in advanced urothelial carcinoma | Prof Thomas Powles at ECC 2015 - 101271

Spotlight
Video

IMvigor 210: Phase 2 trial of atezolizumab, anti-PD-L1, in advanced urothelial carcinoma | Prof Thomas Powles at ECC 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of IMvigor 210, a multicentre, phase 2 clinical trial that was designed to evaluate the efficacy and safety of atezolizumab, an anti-PD-L1 antibody, in patients with locally-advanced or metastatic urothelial carcinoma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 12/17/15
Added : 3 years ago
Category : Urology